Single Core Osmotic Pump (SCOP): Development of Single Layer Osmotic controlled release tablet for poorly soluble drug

Geeta M. Patel^{1*} and Jayendra D. Patel¹

Abstract

A new Single Core Osmotic Pump (SCOP) tablet which osmotically delivers high doses of low solubility drug Sertraline Hydrochloride (SET) has been developed. The formulations were compared based on six comparative parameters namely, Q24 (total release after 24hr), Q12 (total release after 12hr), TL (lag time), RSQzero12 (R square of zero order equation for drug release in 12hr), RR12 (in vitro release rate for 12 hr) and T80% (time required to deliver 80% of drug). The drug release profile from osmotic devices showed that the type of polymer and concentration in the core formulation can markedly affect the drug release. Increasing the amount of osmogen to an optimum level significantly increased Q12 and improved zero order release pattern of SET. Bioavailability enhancing additive, citric acid was added in core formulation, which has multifunction property like enhanced SET solubility, create osmotic pressure difference, act as flux regulating agent and make SET containing composition more hydrophilic. As a result, TL and T80% were decreased and Q12 and RR12 were increased. Increasing concentration of PEG 4000 in the semipermeable membrane of the SCOP markedly decreased TL, T80% and increased Q12, Q24 and RR12. Optimum aperture diameter for the formulations was determined to be 850 μ m for zero order release pattern. This study also revealed that optimization of SPM thickness is very important for approaching zero order kinetics. The developed SCOP system could be effective to formulate a single layer osmotic controlled release tablet of water insoluble drug with large dose.

Introduction

Over the past 50 years, with the recognition of the therapeutic advantages of controlled drug delivery systems, greater attention has been dedicated to development of controlled-release delivery systems. Among various technologies that have been used in the development of controlled drug delivery systems, osmotic pumps hold an important position [1-7]. These are devices that use osmotic pressure as an energy source to deliver drug at predetermined zero-order rates for extended period of time. Though different types of oral osmotic systems have been reported in the literature [8], the single most important osmotic delivery system is Theeuwes elementary osmotic pump [9]. In this system, the osmotic core is surrounded by a semi permeable membrane drilled with a drug delivery orifice. Once this system comes in contact with the gastrointestinal fluids, the osmotically driven water enters the system through the semi permeable membrane, dissolves the soluble agents and exits through the delivery orifice. Because these systems use osmotic pressure for the controlled delivery of the active compound(s), delivery rates are expected to be independent of gastrointestinal conditions [9].

The rate of drug release from osmotic pumps is dependent on total solubility and osmotic pressure of the core. Therefore, poorly water-soluble drugs do not create sufficient osmotic pressure

and are delivered at low rates. To overcome this problem, other types of osmotic pumps for poorly water-soluble drug have been designed [10,11]. In some cases, this problem may be solved by addition of a solubility-modulating agent to the core [12-14]. However, this approach is not satisfactory for cases where a large amount of the modulator is necessary. In addition, rapid depletion of the modulator from the system will cause the device to release the drug at non-uniform rates.

Literature review suggested that single-layer osmotic drug delivery of low solubility drug is possible [15-20], but do not define the limitations or optimal formulation factors for such systems. In the current investigation, factors that influence the successful delivery of low solubility API's from a single-layer osmotic system are investigated.

For the development of single core osmotic pump (SCOP), Sertraline Hydrochloride (SET) was selected as model drug. SET is most commonly prescribed for therapy of depressive illness, in the general dose range 50-200 mg/day. SET also has poor aqueous solubility, particularly at pH values above 6 to 7. This can result in low bioavailability. Patients are generally initiated on SET at a dose of 50 mg/day or less. Patients who do not respond at the 50 mg dose are given higher doses. If necessary to achieve efficacy, higher doses may be reached by gradual increases in dosage. Improved SET dosage forms which exhibit a lower incidence and/or severity of side effects would be advantageous because patient comfort and thus, compliance, would be improved and dosing could be initiated at doses higher than 50 mg without the need for gradual increases. Initiation at higher starting doses would, in turn, be useful by potentially affecting a shorter onset of antidepressant action.

*correspondence: geekhappy2002@yahoo.co.in

¹S K Patel College of Pharmaceutical education and Research, Gujarat, India.

Thus, such an improved SET dosage form which permits oral dosing of high doses of SET (e.g., 60 mg and higher) with relatively reduced side effects would permit wider therapeutic application of SET therapy, and would accordingly provide a significant improvement in dosing compliance and convenience [21-22].

Materials

Sertraline Hydrochloride (SET) was a generous gift from Hetero Drugs Limited (Hyderabad, India). Natrosol (250 H, 250 L), Klucel (EXF, HF) were generous gifts from DKSH India Pvt Ltd. (Mumbai, India). PolyoxWSR Coagulant and Methocel were received as a gift samples from Colorcon Asia Pvt Ltd. (Goa, India). Xanthan Gum was received as a gift sample from Ottochemi (Mumbai, India). Cellulose acetate was received as a gift sample from Eastman Chemical Co. (USA). Neosorb P 30/60 was received as a gift sample from Roquette Asia Pvt. Ltd, Mumbai. Xylitol was received as a gift sample from DaniscoIngradient, USA. Citric acid, Polyethylene glycol 4000 and Sodium lauryl sulphate were purchased from S. D. Fine Chemicals (Mumbai, India). The other chemicals used were of analytical grade.

Experimental

Drug-excipients compatibility study

Assessment of possible incompatibilities between an active drug substance and different excipients forms an important part of the preformulation stage during the development of dosage form. Differential Scanning Calorimeter (DSC TA-60WS) allows the fast evaluation of possible incompatibilities, because it shows changes in the appearance, shift of melting endotherms and exotherms, and/or variations in the corresponding enthalpies of reaction. The DSC thermograms of pure drug SET, polymer Natrosol 250HX, an osmotic agent Neosorb P 30/50 DC and a mixture of drug with polymer Natrosol 250HX, an osmotic agent Neosorb P 30/50 DC and mixture of drug with all excipients in ratio drug: excipients (1:1) used in formulation were recorded. The thermal analysis was performed in a nitrogen atmosphere at a constant heating rate of 10°C/min over a temperature range of 40°C to 300°C.

Drug estimation

UV determination was carried out for drug content uniformity and measure quantity of SET during dissolution test. The response of the sample solution was measured at 274 nm. The amounts of SET present in the sample solution were determined by fitting the responses into the regression equation for SET. A calibration curve was plotted over a concentration range of 100–200 µg/ml.

Formulation development and optimization of core Tablet

Core tablets were prepared by direct compression. In order to select water swellable polymer, formulation were prepared using 10 %w/w core weight of Polyox Coagulant, Methocel K4M, Natrosol 250HX, Xanthan Gum and Klucel HF and their effects on release profiles were determined. The core compositions are summarized in (Table-1). SET was mixed with water swellable polymer for 10 min. After passing

this mixture through 40 mesh sieve, Neosorb P30/60 DC (osmotic agent) and Klucel EXF (binder) were added in geometric dilution and mixing continued for additional 10 min. To this mixture, Sodium lauryl sulphate (wetting agent) and Acryflow-L (lubricant) were added and mixed for additional 5 min. The blend was then compressed to tablet with an average weight of 695 ± 10 mg using rotary tablet machine (Rimek Mini Press-II) equipped with a 13 mm diameter round, plain and standard concave tooling. The average hardness of compressed tablets was 6.5 ± 1.5 kg/cm².

Various formulation and dissolution parameters were analyzed to optimize SCOP. Various parameters, mainly, Q₂₄ (quantity of the drug released within 24 h), Q₁₂ (quantity of the drug released within 12h), TL (lag time of the drug release from device), RSQ_{ZERO 12} (R square of release data of 12h fitted to zero order equation), RR₁₂ (in vitro release rate for 12h) and T_{80%} (time require to deliver 80% of drug), were used to compare different formulations. Formulations with acceptable Q₂₄ (i.e., Q > 70%) and Q₁₂ (i.e., Q > 50%) were adopted for further evaluations. Among selected formulations, those with T_L > 2h were rejected and other formulations were compared in terms of the RSQzero, RR₁₂ and T_{80%}.

Coating and drilling

Core tablets were coated in a conventional laboratory coating pan. Coating solution was prepared by dissolving 16 grams of cellulose acetate CA 398-10 and 8 grams of polyethylene glycol 4000 in a binary solvent mixture of acetone (356 grams) and water (20 grams). Various components of coating solution were added to solvent mixture in sequential manner. The component added first was allowed to dissolve before next component was added. Before starting coating, tablets were warmed at 40 ± 5 °C for 10 minutes and then coating solution was applied at a constant spray rate of 4-5 ml/min. Coating process was done on a batch of 100 tablets. Pan speed was maintained at 20 rpm and hot air inlet temperature

Ingredients	B1	B2	B3	B4	B5	B6
Sertraline HCl (≅ 200 mg of SET)	224	224	224	224	224	224
Polyox Coagulant	-	60	-	-	-	-
HPMC K4M	-	-	60	-	-	-
Natrosol 250 HX	-	-	-	60	-	-
Xanthan Gum	-	-	-	-	60	-
Klucel HF	-	-	-	-	-	60
Neosorb P30/60 DC	322	262	262	262	262	262
Klucel EXF	30	30	30	30	30	30
Citric acid	105	105	105	105	105	105
SLS	18	18	18	18	18	18
Acryflow - L	6	6	6	6	6	6

Table -1: Formulae of SCOP TABLET (mg tablet)

was kept at $40 \pm 5^\circ\text{C}$. Coating was continued until desired % coat weight (10%) was obtained on the core tablets. In order to investigate the effect of coating membrane including amount of plasticizer as well as thickness on drug release, osmotic tablets were coated with different concentration of plasticizer with different membrane thickness shown in Table 2.

Coated tablets were drilled through the one side of each coated tablet by standard mechanical micro drills. To minimize the effect of orifice size on the release of the active, orifice of 850 μm diameter was drilled on the tablets.

In vitro release studies

In vitro release studies of different formulations were performed according to USP apparatus II, paddle method (Dissolution test apparatus-TDT-06T, Electrolab, India). Paddle speed was maintained at 50 rpm and 900 mL of Acetate Buffer pH 4.5 was used as the dissolution medium. Samples (10ml) were collected at predetermined time intervals (1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24 hrs) and replaced with equal volume of fresh medium, filtered through a 0.45 μm filter and analyzed with a UV—Visible spectrophotometer (Shimadzu UV-1700 UV/Vis double beam spectrophotometer) at 274nm. Drug concentration was calculated from a standard calibration plot and expressed as cumulative % drug dissolved.

Surface morphology

To investigate the change in the membrane structure, surface of coated tablets (both before and after dissolution studies) was studied using Scanning Electron microscopy (SEM). When tablet is suspended in the dissolution medium, the coating membrane imbibes water thereby forming pores by leaching the water-soluble pore formers. The changes in the appearance of coating membrane of SCOP during the dissolution process were studied using SEM.

Batch No.	CA:PEG	% Weight Gain	Orifice Diameter	No. of Orifice
B31	6.5:3.5	10	850	1
				2
				4
B32	7.0:3.0	10	850	1
B33	7.5:2.5	10	850	1
B34	8.0:2.0	10	850	1
B35	6.5:3.5	10	350	1
B36	6.5:3.5	10	550	1
B37	6.5:3.5	10	650	1
B38	6.5:3.5	8	850	1

Table 2: Coating membrane composition for SCOP

Burst strength

Burst strength of the exhausted shells ($n = 6$), after 24 h of dissolution, was determined to assure that the tablets would maintain their integrity in the GIT. Burst strength was determined, as the force required to break/rupture the shells after dissolution studies. The texture analyzer (Brookfield's Texture Analyzer – QTS) with a 5 kg load cell and 25mm aluminum cylindrical probe was utilized for this purpose. Test speed of 0.8 mm/s was selected and the distance moved was set at 6 mm.

Accelerated stability studies

Optimized formulation of SCOP was packed in aluminum strips laminated with PVC. According to ICH guideline, the packed formulations were stored in stability chambers (Cintex humidity oven; Cintex Industrial Corporation, Dadar, Mumbai) maintained at 40°C and 75% relative humidity for 3 months. The samples were withdrawn each month and analysed for drug content and drug release rate using UV spectrophotometer.

Results & Discussion

Drug-excipients compatibility study

As shown in (Figures 1A to 1F), DSC thermograms of individual excipients, SET, Natrosol 250HX and Neosorb P 30/60 DC and 1:1 of SET:Natrosol 250HX and SET:Neosorb P 30/60 DC and drug with excipients were obtained and compared. DSC thermogram of SET (Form II) (Figure 1A-1F) show a very small endotherm at 188.44°C ($\Delta H = 7.75 \text{ J/g}$) with onset temperature at about 181.74°C , which corresponds to a solid – solid transition to Form III [23,24]. This event is followed by melting of Form III with an onset at 247.44°C , sharp peak at 250.93°C ($\Delta H = 67.66 \text{ J/g}$) and recovery at 255.56°C , which is in the range of $246 - 251^\circ\text{C}$. Third peak of thermogram at 295.86 may be degradation of SET. So, it can be concluded that transition on the graph is the melting point of the SET [25].

Figure-1B and 1C show peak at 237.01°C ($\Delta H = 12.48 \text{ J/g}$) with onset 227.57 and recovery at 243.06°C and peak at 103.77°C ($\Delta H = 113.39 \text{ J/g}$) with onset at 95.25°C and recovery at 110.92°C for Natrosol 250HX and Neosorb P 30/60 DC, respectively.

Thermogram of SET and Natrosol 250HX mixture (Figure 1D) shows peak for SET with an onset 252.37°C , a maxima at 253.39°C ($\Delta H = 69.25 \text{ J/g}$) and recovery at 263.01°C . Thermogram of SET alone shows sharp peak at 250.93°C ($\Delta H = 67.66 \text{ J/g}$), onset at 247.74°C and recovery at 255.56°C , which indicate that there was no change in peak maxima and enthalpy and hence no interaction between drug and polymer.

Thermogram of SET and Neosorb P 30/60 DC (Figure-1E) show peak for SET with an onset 246.72°C , a maxima at 253.98°C ($\Delta H = 66.26 \text{ J/g}$) and recovery at 255.52°C . Thermogram of SET alone shows sharp peak at 250.93°C ($\Delta H = 67.66 \text{ J/g}$), onset 247.74°C and recovery at 255.56°C , which indicate that there was no changes in peak maxima and enthalpy and hence no interaction between drug and osmogen.

Figure 1A: DSC curve of SET

Figure 1B: DSC curve of Natrosol 250 HX

Figure 1C: DSC curve of Neosorb P 30/60 DC

Figure 1D: DSC curve of SET + Natrosol 250 HX

Figure 1E: DSC curve of SET + Neosorb P 30/60 DC

Figure 1F: DSC curve of SET + Excipients

Figure 1F show thermogram of SET with an excipients: 1) Natrosol 250HX, 2) Neosorb P 30/60 DC, 3) Klucel EXF and 4) SLS show no significant change in peak maxima at 252.63 ($\Delta H = 69.25$ J/g), onset at 250.21 and recovery at 261.48 in comparison with Figure 1A of SET alone having at 250.93 °C ($\Delta H = 67.66$ J/g), onset 247.74 °C and recovery at 255.56 °C. No significant changes in enthalpy, peak onset, peak maxima and recovery peak were noted in all these cases indicating compatibility of SET with used excipients.

Drug estimation

A linear correlation was obtained between peak areas versus concentration of SET in the range of 100 to 200 µg/ml. The % recovery was found to be varying from 98.43 ± 0.491 to 101.91 ± 0.6148 indicate that proposed method was accurate. Each measurement represented the average of three replicates. The slope of regression line, y-intercept and correlation coefficient were 0.0029, 0.0331 and 0.9997 respectively.

Formulation development and optimization of core tablet

Influence of water swellable polymer

In this study, different core formulations were made using 10%w/w of core weight of Natrosol 250HX, Polyox WSR Coagulant, Xanthan Gum, Klucel HF and HPMC K4M. Q_{24} were 43.24%, 38.12% and 39.80% for the osmotic device containing Xanthan Gum, Klucel HF and HPMC K4M, respectively. These polymers do not appear to be different from the control (Q_{24} was 34.30%), which has no water swellable polymer; further more RSQ_{ZERO12} for formulation containing Klucel HF and HPMC K4M were 0.8506 and 0.9113 respectively, which indicate that these polymer did not show good release profile. However, hydroxy ethyl cellulose (Natrosol 250HX) and PolyoxWSR Coagulant appears to be quite effective. These two polymer show good release profile. For formulation containing 10% core weight of Natrosol 250HX and Polyox WSR Coagulant, Q_{24} were 70.30% and 59.67%, RSQ_{ZERO12} were 0.9899 and 0.9852 and RR_{12} were 10.88 and 8.38, respectively. Figure 2 shows the effect of water swellable polymers on drug release.

However, shortest lag time (T_L : 1.12h), good release rate (RR_{12} : 10.88) and amount of drug release within 12h (Q_{12} : 59.34) demonstrate that Natrosol 250HX is the first choice for SCOP system to obtain zero order release and reasonable amount of drug release for a period of 24h.

At a given extrusion pressure, the extrusion rate typically slows with increased viscosity. Applicants have surprisingly determined that high molecular weight hydroxyethyl cellulose (Natrosol 250HX) in combination with the drug particles form high viscosity solutions with water but are still capable of being extruded from the tablets with a relatively low force. The effectiveness of HEC is possibly related to its rheological properties and rate of hydration [26]. Also, the pressure produced during swelling did not lead to rupture of the system. The results also showed that uniform rate of swelling of the polymer ensured that the drug is released at a relatively constant rate (RSQ_{ZERO12} : 0.9899). According to observed results, Natrosol 250HX was adopted for further investigation.

Influence of different osmotic agent

A number of potential osmotic agents having different osmotic pressures were examined. Figure 3 shows release profiles of formulations containing Mannogem, Neosorb P30/60 DC, Pharmaburst 500 and Xylitab as osmotically active agents. The figure indicates that the highest Q_{12} and shortest T_L were obtained from the devices containing NeosorbP30/60 DC (Q_{12} : 56.17 and T_L : 1.15h). Comparing RSQ_{ZERO12} values of release data from osmotic devices containing 262 mg of Mannogem, Neosorb P30/60 DC, Pharmaburst 500 and Xylitab showed the highest RSQ_{ZERO12} for the device containing Neosorb P30/60 DC (RSQ_{ZERO12} was 0.9950, 0.9886, 0.9205 and 0.9850 for Neosorb P30/60 DC, Xylitab, Mannogem and Pharmaburst 500, respectively). Q_{24} for Xylitab was slightly greater than Neosorb P30/60 DC. However, shortest T_L and higher Q_{12} , RR_{12} and RSQ_{ZERO12} of Neosorb P30/60 DC demonstrate that Neosorb P30/60 DC is the first choice for SCOP system to obtain zero order release and reasonable amount of drug release for a period of 24h. In other words, osmotic pumps containing Neosorb P30/60 DC as the osmotic agent followed zero order release pattern. The results also showed that the presence of Neosorb P30/60 DC markedly diminished T_L of the drug release from osmotic system (1.15 h for Neosorb P30/60 DC versus 1.3h, 3h and 3.3 h for Xylitab, Mannogem and Pharmaburst 500, respectively, $p < 0.05$). The lowest Q_{24} (54.64%) and longest T_L (3.3h) were related to formulation which contained Pharmaburst 500 as osmotic agent. The lowest release rate for the devices containing Pharmaburst 500 could be due to a low osmotic activity [27]. Therefore, formulation containing 262mg of Neosorb P 30/60 DC was adopted for further investigation.

Influence of solubilizer

There are a variety of factors to consider when choosing an appropriate organic acid [28] for use as a solubilizer with SET. An organic acid meeting such criteria is citric acid, which has very high water solubility (>2000mg/ml), high ratio of equivalents of acid per gram (15.6 mEq/g) and high osmotic pressure.

Figure 4 show release profile of formulation containing different concentration of citric acid. Q_{12} were 61.68%, 62.45%, 62.17%, 68.42%, 69.98% and 73.42% for 0%, 3%, 6%, 9%, 12% and 15% of citric acid of core weight. It indicates that drug release increased as amount of citric acid was increased.

$T_{80\%}$ for formulation containing 0, 3, 6, 9, 12 and 15% of citric acid were 24, 22, 22, 18, 18 and 16h. These result indicate that amount of citric acid had a pronounced effect on release profile of SET from osmotic systems. However, T_L and RR_{12} were relatively same for formulation containing 9, 12 and 15% of citric acid (T_L : 0.45 for all three formulations and RR_{12} : 12.77mg/h, 13.06mg/h and 13.71mg/h, respectively ($p = 0.03$). Because of shortest $T_{80\%}$ (16h) and higher correlation coefficient of zero-order kinetic (RSQ_{ZERO12} : 0.9948) of the formulation containing 15% of citric acid in comparison with the tablets containing 9% and 12% of citric acid (T_L : 18h and 18h and RSQ_{ZERO12} : 0.9913 and 0.9907, respectively), was adopted as a suitable formulation and further investigations were carried out

Figure 2: Influence of hydrophilic polymer on *in vitro* SET release

Figure 3: Influence of osmogent on *in vitro* SET release

Figure 4: Influence of different concentration of citric acid on in vitro SET release

Figure 5: Release profile of SET from formulation containing different concentration of PEG 4000 in the SPM formulation

Figure 6: Release profile of SET from osmotic device with different SPM thicknesses

on this formulation to examine the effect of coating parameters, mainly the number and size of orifice, thickness of coating and the concentration of plasticizers.

Influence of coating and drilling

Based on the above results, optimized tablet formulation B4 was adopted in the following study. The membrane was also an important factor for the release profile of SCOP. Plasticizers are added to modify the physical properties and improve film-forming characteristics of polymers. As plasticizers will also affect the permeability of polymer films it is important to investigate the effect of plasticizer on the release rate of drug from osmotic devices. As PEG is a hydrophilic plasticizer, it could be leached easily and left behind wholly porous structure, which increases membrane permeability and drug release rate. Water permeation through the coating is affected by the cellulose acetate: PEG (CA: PEG) ratio used in the formulation of the coating solution. To study the influence of amount of PEG on drug release, the CA membranes were plasticized with different ratio of PEG. Figure 5 shows the release profiles of formulations containing different amounts of plasticizer. Q_{12} for membrane containing CA: PEG ratio of 6.5:3.5, 7.0:3.0, 7.5:2.5 and 8.0:2.0 were 73.42%, 66.45%, 62.1% and 58.63% respectively. Results shows that increase of PEG level led

to an increase of drug release rate. The more PEG incorporated into the CA membrane, the more void space formed after leaching and, in turn, the higher the permeability of the membrane, the higher the drug release rate obtained.

PEG 4000, which was added to the coating formulation as hydrophilic plasticizer, can increase the hydrophilicity of semi-permeable membrane (SPM) and increase the rate of water penetration across the membrane and thus, decrease lag time of osmotic systems (T_L were 0.3, 0.3, 0.45 and 2.15h for membrane containing CA:PEG ratio of 6.5:3.5, 7:3, 7.5:2.5 and 8:2, respectively). Similar results were reported about relationship between water imbibition and $T_{80\%}$. $T_{80\%}$ for membrane containing CA: PEG ratio of 6.5:3.5, 7:3 and 7.5:2.5 were 15, 20 and 24h, respectively. On the contrary, 80% of drug release was not observed with membrane containing CA: PEG ratio of 8.0:2.0. It can be concluded that a good hydrophilic/lipophilic balance in SPM structure is required to achieve desirable release profile with zero order kinetics. It can be predicted from the figure that membranes containing CA: PEG in ratio of 6.5:3.5 is optimum in SPM formulation for SCOP to obtain zero order release device.

The most straightforward method to modify the drug-release profile of SCOP formulation is to vary the coating weight. Proper selection and optimization of the SPM thickness is one of the best

Figure 7: Release profiles of SET from osmotic devices with different orifice size

ways to achieve a constant release rate of drugs from osmotic tablets. Figure 6 represents the release profiles of osmotic devices formulated with different SPM thicknesses. The optimal tablets were coated to obtain weight gain of 8%, 10% 12% and 14% of core weight, respectively (CA: PEG ratio, i.e. 6.5:3.5 was constant for all formulation). SPM having 8% of weight gain cracked and disintegrated after the exposure of the tablet to the dissolution medium.

Figure 6 shows that increasing the membrane thickness increased resistance of the membrane to diffusion of dissolution medium followed by a reduction in the liquefaction rate of the tablet core which, ultimately, reduced drug release rate from osmotic devices. Results shows that increasing coating weight from 10% to 14% increased lag time and decreased Q_{24} significantly (T_L was 0.3, 0.45 and 1.3h and Q_{24} was 89.08, 83.92 and 75.68 for formulation containing 10, 12 and 14% of coating weight, respectively, $p < 0.05$). Evaluation of the parameters related to release kinetics revealed that the drug release from formulation having 10% coating weight of core weight followed zero order kinetics ($RSQ_{ZERO\ 12}$ was 0.9965) in comparison with formulation having 12% and 14% of coating weight of core weight ($RSQ_{ZERO\ 12}$ was 0.9950 and 0.9952, respectively). These results demonstrated that SPM thickness should be optimized in order to ensure that the pressure produced during swelling does not lead to rupture of the system and also moisten the tablet in acceptable time range. Optimization of SPM thickness makes the

osmotic system suitable in the case of release rate, release kinetics, lag time and other basic features.

Aperture diameter is one of the critical parameters that influences release rate, lag time and release kinetics of the osmotic drug delivery devices [29]. Thus, the size of delivery orifice must be optimized in order to control the drug release from osmotic systems. Figure 7 shows the release profiles of the drug from formulations with different aperture diameters. The orifice sizes of 350, 550, 650 and 850 μm were drilled by mechanical drill on each side of the surface. No significant difference was observed between release rate of drug and the orifice diameter between 350 and 550 μm . However, results showed significant changes in some of the release parameters due to the change in orifice size of 350 and 550 μm . More specifically, T_L and $RSQ_{ZERO\ 12}$ were remarkably improved ($p < 0.05$) by increasing the aperture diameter from 350 to 550 μm (T_L : 1 and 0.45h while $RSQ_{ZERO\ 12}$ were 0.9923 and 0.9942 for orifice size of 350 and 550 μm respectively). Q_{24} was increased and lag times of the systems were decreased significantly as increasing the orifice diameter. Q_{24} was increased from 80.84% with 350 μm to 89.08% with 800 μm orifice size. Lag time was decreased from 1h to 0.3h as the orifice size was increased from 350 μm to 850 μm ($p < 0.05$) respectively. These results indicate the importance of orifice diameter on the control of drug release from the SCOP.

Among these, formulations having 850 μ m orifice size had highest Q_{24h} and $T_{80\%}$ and shortest lag time (Q_{24h} : 89.08%, $T_{80\%}$: 16h and T_L : 0.3h, $p = 0.02$). These results indicated that optimum aperture size in SCOP systems is considerably larger than ordinary Elementary Osmotic Pump (EOP) systems which are used for delivering high to moderately water-soluble drugs [29]. This difference probably originates from different mechanisms of drug release between these systems. EOPs generally released their drug content in soluble form [29] whereas SCOP releases the drug in soluble and in suspended solid particle forms concurrently.

SEM study

To investigate the change in the membrane structure during dissolution process, surface of coated tablets (both before and after dissolution studies) were studied using Scanning Electron Microscopy (SEM) [30]. The changes in the appearance of coating membrane of SCOP during the dissolution process are shown in Figure 8. As soon as the tablet is suspended in the dissolution medium, the coating membrane imbibes water thereby forming pores by leaching the water-soluble pore formers.

Figure 8A shows membrane structure before dissolution; initially the surface of coated tablets was smooth before coming into contact with aqueous environment and coats appeared to be free of point defects. SEM of the micro porous structure of the membrane after dissolution is shown in Figure 8B. This significant change in porosity has resulted from the leaching of water-soluble additive, i.e. PEG 4000, during dissolution and this increased the permeability of membrane.

Burst strength

After 24hr of dissolution studies, exhausted tablets were evaluated for burst strength to assure that the tablets maintain their integrity in GIT and do not lead to dose dumping. Figure 9 and 10 shows the dependence of burst strength of the exhausted shells on coat thickness and amount of plasticizer, respectively. Figure 9 show effect of coating thickness on burst strength. As coating weight of tablet increase, membrane becomes thicker, leading to increase in burst strength (Burst strength was 3724g and 6913g for 10% and 14% of coating weight, respectively, $p < 0.05$) another parameter that affects burst strength is the level of plasticizer of coating membrane. With the increase in level of PEG-4000, the membrane became more porous after exposure to water, leading to a decrease in its strength (Burst strength was 3724 g and 4901g for 6.5:3.5 and 8.0:2.0 CA: PEG ratio, respectively). In all cases, the value is much higher than the mechanical destructive forces in GIT [31-32], thus assuring that the formulations can be expected to remain intact in GIT without any incidence of dose dumping. For optimized coating weight gain (10%) and CA: PEG ratio (6.5:3.5), burst strength was 3724g (37.24N), which indicate that SCOP remain intact in GIT.

Accelerated stability studies

An ethical drug manufacturer is committed to provide his consumers with drug products that are both efficacious and safe. This can only be ensured by instituting a program to study the stability of a product during its various phases of development and to use proper storage conditions and comply with the expiry period under those conditions.

With the recent trend toward globalization of manufacturing operations, it is imperative that the final product is sufficiently robust for marketing worldwide under a variety of climatic conditions, including tropical, subtropical, and temperate. The optimized formulation of SCOP containing SET was subjected to accelerated stability studies in an aluminum/aluminum strips to be the best protecting packaging materials, and it is used as packing material in the present study. Batch no. B4 was packed in an aluminum/aluminum strip and subjected to short-term stability studies at $40 \pm 2^\circ\text{C}$ and $75 \pm 5\%$ relative humidity for 90 days.

Samples withdrawn each month showed no significant change in physical appearance, drug content, and *in vitro* drug release characteristics. So, the formulations were found to be stable in terms of drug content and *in vitro* drug release after stability study, the *in vitro* drug release profiles of tablets are compared for various dissolution parameters shown in Table 3 for SET release. The values of different dissolution parameters showed that there was no significant difference between *in vitro* drug release profile of initial and after stability studies ($p < 0.05$).

Conclusion

The present study aimed to develop an oral osmotic system, SCOP which delivered the SET with controlled rate up to 24 h. The core contains hydroxyethyl cellulose (Natrosol 250HX), which serves to entrain the drug particles as they are extruded out a hole in the coating at one end of the tablet, and a sugar, which provides the osmotic driving force for water imbibition. The Single Core Osmotic Pump (SCOP) was simple to prepare, because there is no need for a push compartment, and is simpler with regard to orifice drilling compared with the push-pull osmotic tablet. Optimized formulation was found to be able to deliver drug at a rate of approximately zero order up to 12h. The rate of the drug release from these tablets increased with increased concentrations of the osmogen and the plasticizers but decreased with increased coating thickness. This study also revealed that it was possible to formulate a single layer osmotic controlled release tablet of water insoluble drug with large dose.

	Assay of SET	T_{Lh}	$Q_{12\%}$	$Q_{24\%}$	$RSQ_{ZERO 12}$
Initial	100 ± 3.02	1.12	59.34	70.30%	0.9899
After 30 days	100 ± 2.41	1.11	58.89	70.01	0.9897
After 60 days	100 ± 2.14	1.12	58.49	69.89	0.9895
After 90 days	99 ± 1.12	1.01	58.11	69.45	0.9897

Table 3: Comparison of dissolution parameter after stability study

8A Before Dissolution

8B After Dissolution

Figure 8: Membrane structure of SCOP A) before and B) after dissolution

Figure 9: Effect of coating weight on burst strength

Figure 10: Effect of amount of plasticizer on burst strength

Conflict of interest

There is no interest of all authors in financial and personal relationship with any other people or any organization for publishing this research article or financial support for research work.

Acknowledgement

Authors want to hearty acknowledge all the listed companies for providing generous gifts for drug and other excipients.

Article history

Editor: S Pattnaik, Biju Pattnaik University of Technology, India

Reviewer: Amusa S. Adebayo, Roosevelt University, USA.

Received: 24-Dec-2011 Revised: 29-Feb-2012 Re-Revised: 06-

Mar-2012 Accepted: 07-Mar-2012 Published: 27-Mar-2012

References

- Theeuwes, F: **OROS osmotic system development**. *Drug Dev. Ind. Pharm.* 1983 **9**: 1331-135.
- Zentner, GM, Rork, GS, Himmelstein K. J: **The controlled porosity osmotic pump**. *J. Contr. Rel.* 1985, **1**: 269-282.
- Bindschaedler C, GummyR, Doelker E: **Osmotically controlled drug delivery systems produced from organic solutions and aqueous dispersions of cellulose acetate**. *J. Contr. Rel.* 1986, **4**: 203-212.
- Lindstedt B, Ragnarsson G, Hjartstam J: **Osmotic pumping as a release mechanism for membrane coated drug formulations**. *Int. J. Pharm.* 1989, **56**: 261-268.
- Appel L E, Zentner G M: **Use of modified ethylcellulose lattices for microporous coating of osmotic tablets**. *Pharm. Res.* 1991, **8**: 600-604.
- Zentner M, McClelland GA, Sutton SC: **Controlled porosity solubility- and resinmodulated osmotic delivery systems for release of diltiazem hydrochloride**. *J. Contr. Rel.*, 1991, **16**: 237-244.
- Okimoto K, Ohike A, Ibuki R, Aoki O, Rajewski RA: **Design and evaluation of an osmotic pump tablet (OPT) for chlorpromazine using (SBE)**. *Pharm. Res.*, 1999, 5549-554.
- Santus G, Baker R W: **Osmotic drug delivery: a review of the patent literature**. *J. Contr. Rel.* 1995, **35**: 1-21.
- Theeuwes F: **Elementary Osmotic Pump**. *J. Pharm. Sci.*, 1975, **64**: 1987-1991.
- Khanna S C: **Therapeutic system for sparingly soluble active ingredients**. *US Patent Number* 4,992, 2781, 991.
- Swanson D R, Barclay B L, Wong P S L, Theeuwes F: **Nifedipine gastrointestinal therapeutic system**. *Ameri. J. Med.*, 1987, **83**: 3-9.
- Ayer A D, Wong P S L, **Dosage form comprising solubility regulating member**. *US Patent* 4,755,180,1988.
- Magruder PR, Barclay B, Wong P, Theeuwes F: **Composition comprising a therapeutic agent and a modulating agent**. *US Patent* 4,851,229, 1989.
- McClelland G. A., Sutton S C, Engle K, Zentner G M: **The solubility-modulated osmotic pump: In vitro-in vivo release of diltiazem hydrochloride**. *Pharm. Res.* 1991, **8**: 88-92.
- Khanna SC, Ruettimann T: **Oral therapeutic system having systemic action**. *US Patent* 4, 857, 336, 1987.
- EX. Lu, Jiang ZQ, Zhang Q, Jiang G: **A water-insoluble drug monolithic osmotic tablet system utilizing gum Arabic as an osmotic, suspending and expanding agent**. *J. Control. Release*; 2003, **3**: 375-382.
- Liu X, Chen D., Zhang R, **Evaluation of monolithic osmotic tablet system for nifedipine delivery in vitro and in vivo**. *Drug Dev. Ind. Pharm.* 2003, **7**: 813-819.
- ShokriJ, AhmadiP, RashidiP, ShahsavariM, Rajabi-Siahboomi A, NokhodchiA: **Swellable elementary osmotic pump (SEOP): an effective device for delivery of poorly water-soluble drugs**. *Eur. J. Pharm.* 2008, **2**: 289-297.
- Kenneth C., Waterman E LT **Osmotic delivery system**. *US Patent* 0161882 A1, 2003.
- Anne B, Rebecca C, **Osmotic delivery system**. *US Patent* 0175346 A1, 2003.
- William J, **Hydrogel - Driven Layered Drug Dosage Form**. *US Patent* 6,899,896 B2,2005.
- Mary Tanya Am Ende, **Sertraline Salts and Sustained release Dosage Forms of Sertraline**. *US Patent* 6,517,866 B1, 2003.
- Rober J Sysko, Douglas JM, **Sertraline Polymorph**. *US Patent*: 5248699, 1993.
- Eduard Schwartz, Tamar Nidam, Anita Liberman, Marioara Mendelivici, **Method for preparation of Sertraline HCl Polymorph**. *US Patent*: 6600073 B1, 2003.
- Schwartz Eduard, Nidam Tamar, Liberman Anita, **Sertraline hydrochloride polymorphs**. *US Patent* 7022881,2006.
- Kenneth C. Waterman, Bruce C. MacDonald, Micheal C. Roy, **Extrudable core system: Development of single layer osmotic controlled release tablet**. *J. of contr. Rel.*, 2009, **134(3)**: 201-206.
- Biliote Anne Martine, **Osmotic delivery system**, *European Patent No.* EP 1469826 B1, 2006.
- William Stern, Tenaflly NJ, **Nasal Calcitonin Formulation**. *US Patent No.* RE40, 812, 2009.
- Javad Shokari, Parinaz ahmadi, Parisa Rashidi, **Swellable elementary osmotic pump (SEOP): An effective device for delivery of poorly water-soluble drugs**. *European J. of Pharm. and Biopharm.*, 2008, **68(2)**: 289-297.
- R B Patel, G N Patel, H R Patel, M M Patel, **Inlay osmotic pump tablets containing metformin and glipizide**. *Drug development and industrial pharmacy*, 2011 **37(10)**: 1244-1252
- Kamba, M.; Seta, Y.; Kusai, A.; Ikeda, M.; Nishimura, K. **A unique dosage form to evaluate the mechanical destructive forces in the gastrointestinal tract**. *Int. J. Pharm.*, 2000, **208**: 61-70.
- Kamba M, Seta Y, Kusai A, Nishimura K, **Evaluation of the mechanical destructive force in the stomach of dog**. *Int. J. Pharm.*, 2001, **228**: 209-217.

Citation:

Patel G M and Patel J D: **Single Core Osmotic Pump (SCOP): Development of Single Layer Osmotic controlled release tablet for poorly soluble drug**. *journal of Pharmaceutical Technology and Drug Research* 2012, **1**:1.
http://dx.doi.org/10.7243/2050-120X-1-1